The Global Companion Diagnostics Market was valued at USD 7.9 billion in 2025 and is estimated to grow at a CAGR of 11.2% to reach USD 22.5 billion by 2035.
Growth in the Companion Diagnostics Market is fueled by the increasing prevalence of cancer, the rising occurrence of adverse drug reactions, and the expanding adoption of precision medicine across healthcare systems. Companion diagnostics are specialized medical tests designed to determine which patients are most likely to respond to a targeted therapy or may face a greater risk of treatment-related adverse effects. These diagnostic solutions identify biomarkers, genetic alterations, and protein expression patterns that support personalized treatment selection and improve clinical decision-making. Their growing role in precision medicine has significantly increased their importance in modern healthcare, particularly for therapies that require biomarker-guided patient selection. As cancer cases continue to increase worldwide, healthcare providers are placing greater emphasis on accurate molecular testing to improve treatment effectiveness and patient outcomes. The ongoing transition from standardized treatment approaches toward personalized healthcare strategies is further strengthening market demand, as biomarker-based diagnostics enable more precise therapeutic interventions and contribute to better clinical results while supporting the continued advancement of targeted medicine.
The consumables segment accounted for a 62.1% share in 2025. This segment includes assay kits, reagents, antibodies, probes, cartridges, and other testing materials required during companion diagnostic procedures. These products serve as essential components of molecular and genetic testing workflows by enabling the identification of biomarkers, gene mutations, and other disease-specific characteristics used to guide targeted treatment decisions. Their importance continues to increase as biomarker-driven testing becomes an integral part of precision medicine, supporting accurate patient selection and personalized therapeutic strategies across a wide range of clinical applications.
The pharmaceutical and biopharmaceutical companies segment held 38.3% share in 2025. These organizations integrate companion diagnostics throughout multiple stages of the drug development process to identify appropriate patient populations and support the advancement of targeted therapies. The increasing use of biomarker-based approaches within clinical development programs is helping improve treatment effectiveness, optimize clinical trial performance, and support regulatory approval efforts, contributing to continued demand for companion diagnostic technologies.
North America Companion Diagnostics Market held a 33.3% share in 2025. Rising concerns regarding adverse drug reactions are encouraging broader adoption of companion diagnostic solutions throughout the region. Biomarker-based testing enables healthcare providers to identify patients who are more likely to benefit from specific therapies while minimizing the risk of treatment-related complications. The growing emphasis on personalized healthcare and precision treatment approaches continues to strengthen demand for companion diagnostics across the North American market.
Major companies operating in the Global Companion Diagnostics Market include F. Hoffmann-La Roche Ltd, Foundation Medicine, QIAGEN, Agilent Technologies, Abbott Laboratories, Illumina, Thermo Fisher Scientific, Guardant Health, Myriad Genetics, BioMérieux, Leica Biosystems, MolecularMD, ARUP Laboratories, Bio-Rad Laboratories, and Sysmex Corporation. Companies participating in the Companion Diagnostics Market are reinforcing their market position by investing in biomarker discovery, expanding molecular diagnostic capabilities, and strengthening research and development activities. Many organizations are focusing on developing advanced diagnostic assays that support precision medicine and improve targeted therapy selection. Strategic collaborations between diagnostic developers and pharmaceutical companies are accelerating the co-development of companion diagnostics alongside innovative therapies, helping expand commercial opportunities and improve regulatory success.
This product will be delivered within 2-4 business days.
Growth in the Companion Diagnostics Market is fueled by the increasing prevalence of cancer, the rising occurrence of adverse drug reactions, and the expanding adoption of precision medicine across healthcare systems. Companion diagnostics are specialized medical tests designed to determine which patients are most likely to respond to a targeted therapy or may face a greater risk of treatment-related adverse effects. These diagnostic solutions identify biomarkers, genetic alterations, and protein expression patterns that support personalized treatment selection and improve clinical decision-making. Their growing role in precision medicine has significantly increased their importance in modern healthcare, particularly for therapies that require biomarker-guided patient selection. As cancer cases continue to increase worldwide, healthcare providers are placing greater emphasis on accurate molecular testing to improve treatment effectiveness and patient outcomes. The ongoing transition from standardized treatment approaches toward personalized healthcare strategies is further strengthening market demand, as biomarker-based diagnostics enable more precise therapeutic interventions and contribute to better clinical results while supporting the continued advancement of targeted medicine.
The consumables segment accounted for a 62.1% share in 2025. This segment includes assay kits, reagents, antibodies, probes, cartridges, and other testing materials required during companion diagnostic procedures. These products serve as essential components of molecular and genetic testing workflows by enabling the identification of biomarkers, gene mutations, and other disease-specific characteristics used to guide targeted treatment decisions. Their importance continues to increase as biomarker-driven testing becomes an integral part of precision medicine, supporting accurate patient selection and personalized therapeutic strategies across a wide range of clinical applications.
The pharmaceutical and biopharmaceutical companies segment held 38.3% share in 2025. These organizations integrate companion diagnostics throughout multiple stages of the drug development process to identify appropriate patient populations and support the advancement of targeted therapies. The increasing use of biomarker-based approaches within clinical development programs is helping improve treatment effectiveness, optimize clinical trial performance, and support regulatory approval efforts, contributing to continued demand for companion diagnostic technologies.
North America Companion Diagnostics Market held a 33.3% share in 2025. Rising concerns regarding adverse drug reactions are encouraging broader adoption of companion diagnostic solutions throughout the region. Biomarker-based testing enables healthcare providers to identify patients who are more likely to benefit from specific therapies while minimizing the risk of treatment-related complications. The growing emphasis on personalized healthcare and precision treatment approaches continues to strengthen demand for companion diagnostics across the North American market.
Major companies operating in the Global Companion Diagnostics Market include F. Hoffmann-La Roche Ltd, Foundation Medicine, QIAGEN, Agilent Technologies, Abbott Laboratories, Illumina, Thermo Fisher Scientific, Guardant Health, Myriad Genetics, BioMérieux, Leica Biosystems, MolecularMD, ARUP Laboratories, Bio-Rad Laboratories, and Sysmex Corporation. Companies participating in the Companion Diagnostics Market are reinforcing their market position by investing in biomarker discovery, expanding molecular diagnostic capabilities, and strengthening research and development activities. Many organizations are focusing on developing advanced diagnostic assays that support precision medicine and improve targeted therapy selection. Strategic collaborations between diagnostic developers and pharmaceutical companies are accelerating the co-development of companion diagnostics alongside innovative therapies, helping expand commercial opportunities and improve regulatory success.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Product, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Therapy Areas, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Technology, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Foundation Medicine
- QIAGEN
- Agilent Technologies
- Abbott Laboratories
- Illumina
- Thermo Fisher Scientific
- Guardant Health
- Myriad Genetics
- BioMérieux
- Leica Biosystems
- MolecularMD
- ARUP Laboratories
- Bio-Rad Laboratories
- Sysmex Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 7.9 Billion |
| Forecasted Market Value ( USD | $ 22.5 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
